CN104994858A - Tec家族激酶抑制剂辅助疗法 - Google Patents

Tec家族激酶抑制剂辅助疗法 Download PDF

Info

Publication number
CN104994858A
CN104994858A CN201380065469.7A CN201380065469A CN104994858A CN 104994858 A CN104994858 A CN 104994858A CN 201380065469 A CN201380065469 A CN 201380065469A CN 104994858 A CN104994858 A CN 104994858A
Authority
CN
China
Prior art keywords
tec family
cancer
family kinase
cell
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380065469.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·J·巴吉
T·莫迪
理查德·B·洛夫
约翰·C·伯德
贝蒂·张
詹森·A·杜博夫斯基
纳塔拉詹·穆图萨米
艾米·乔·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104994858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Priority to CN202010271248.7A priority Critical patent/CN111329989A/zh
Publication of CN104994858A publication Critical patent/CN104994858A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CN201380065469.7A 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法 Pending CN104994858A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010271248.7A CN111329989A (zh) 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722107P 2012-11-02 2012-11-02
US61/722,107 2012-11-02
US201361785868P 2013-03-14 2013-03-14
US61/785,868 2013-03-14
PCT/US2013/068132 WO2014071231A1 (en) 2012-11-02 2013-11-01 Tec family kinase inhibitor adjuvant therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010271248.7A Division CN111329989A (zh) 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法

Publications (1)

Publication Number Publication Date
CN104994858A true CN104994858A (zh) 2015-10-21

Family

ID=50628113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380065469.7A Pending CN104994858A (zh) 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法
CN202010271248.7A Pending CN111329989A (zh) 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010271248.7A Pending CN111329989A (zh) 2012-11-02 2013-11-01 Tec家族激酶抑制剂辅助疗法

Country Status (22)

Country Link
US (4) US9717731B2 (https=)
EP (1) EP2914263A4 (https=)
JP (3) JP2015536950A (https=)
KR (1) KR20150080592A (https=)
CN (2) CN104994858A (https=)
AU (3) AU2013337663A1 (https=)
BR (1) BR112015010059A2 (https=)
CA (1) CA2890111A1 (https=)
CL (1) CL2015001147A1 (https=)
CR (1) CR20150242A (https=)
DO (1) DOP2015000098A (https=)
EA (1) EA201590822A1 (https=)
HK (1) HK1214508A1 (https=)
IL (1) IL238548A0 (https=)
MX (2) MX2015005633A (https=)
NI (1) NI201500062A (https=)
PE (1) PE20151604A1 (https=)
PH (1) PH12015500985A1 (https=)
SG (1) SG11201503459SA (https=)
TN (1) TN2015000170A1 (https=)
TW (1) TW201427664A (https=)
WO (1) WO2014071231A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108732280A (zh) * 2017-04-18 2018-11-02 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
CN109641002A (zh) * 2016-08-02 2019-04-16 美国杰龙生物医药公司 血液癌症的组合治疗

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
JP6800750B2 (ja) * 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
WO2015084892A1 (en) * 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20150361504A1 (en) * 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
CA2954725A1 (en) 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
WO2016044774A1 (en) * 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7258462B2 (ja) 2015-05-29 2023-04-17 ポートラ ファーマシューティカルズ， エルエルシー Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
EP3328380A4 (en) * 2015-07-31 2019-07-24 Pharmacyclics LLC INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
SG11201802961PA (en) * 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
JP2019532997A (ja) 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｂｔｋ阻害剤との併用療法
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
WO2019014684A1 (en) * 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
US11897917B2 (en) 2017-09-27 2024-02-13 The University Of York Bioconjugation of polypeptides
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN111110685A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 一种含伊布替尼的药物组合物及其应用
KR20220061149A (ko) * 2019-09-09 2022-05-12 더 칠드런스 호스피탈 오브 필라델피아 Clec16A 기능장애 또는 손실과 관련된 장애의 치료를 위한 조성물 및 방법
US20210106584A1 (en) 2019-10-14 2021-04-15 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN112779285B (zh) * 2019-11-11 2023-01-06 百奥赛图(北京)医药科技股份有限公司 人源化il-10和il-10ra基因改造动物的构建方法和应用
US11814390B2 (en) 2020-01-22 2023-11-14 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US20230158030A1 (en) * 2020-04-10 2023-05-25 Ohio State Innovation Foundation Methods and composition for treatment of covid-19 illness requiring hospitalization
EP4161922A4 (en) * 2020-06-08 2024-07-03 Icahn School of Medicine at Mount Sinai USE OF MULTIKINASE INHIBITORS FOR THE TREATMENT OF RNA VIRUS INFECTIONS
US20250213587A1 (en) * 2022-04-05 2025-07-03 Corvus Pharmaceuticals, Inc. Itk inhibitors for increasing th1 cell activity
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
WO2024206869A2 (en) * 2023-03-30 2024-10-03 Board Of Regents, The University Of Texas System Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
WO2025085889A1 (en) * 2023-10-20 2025-04-24 Corvus Pharmaceuticals, Inc. Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306599A1 (en) * 2009-11-25 2011-12-15 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1240899A3 (en) 1996-01-23 2004-05-19 Ribapharm, Inc. Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP1254911A1 (en) 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
EP1118000A1 (en) 1998-09-28 2001-07-25 Diacrin, Inc. Determining resistance to treatment for hepatitis c virus
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CA2306039A1 (en) 1999-04-19 2000-10-19 Schering Corporation Hcv combination therapy
AU1233701A (en) 1999-10-29 2001-05-14 Board Of Regents, The University Of Texas System Methods and compositions for treating atheroma, tumors and other neoplastic tissue
AU2001249120A1 (en) 2000-03-09 2001-09-17 Schering Corporation Hiv immune adjuvant therapy
EP1299560A2 (en) 2000-05-18 2003-04-09 Genetics Institute, LLC Identification and modulation of t helper-1 and t helper-2 cells
AU2002213343A1 (en) 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
US7314623B2 (en) 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US20070122417A1 (en) 2003-09-30 2007-05-31 Patrick Holt Immunotherapy method
NZ568212A (en) 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
WO2007059329A2 (en) 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
CN105363034A (zh) 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
US20110218512A1 (en) 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
CN102257159A (zh) 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
AR076344A1 (es) 2009-04-20 2011-06-01 Genentech Inc Metodo de terapia complementaria contra el cancer
CA3007787C (en) * 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
EP2640359A4 (en) * 2010-11-18 2015-11-04 Gen Hospital Corp NOVEL COMPOSITIONS AND USES OF HYPOTENSE AGENTS IN THE TREATMENT OF CANCER
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306599A1 (en) * 2009-11-25 2011-12-15 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE A. HONIGBERG等: "The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy", 《PNAS》 *
不详: "View of NCT01217749 on 2012_04_16", 《网址：HTTPS://CLINICALTRIALS.GOV/ARCHIVE/NCT01217749/2012_04_16》 *
姜文奇等: "《肿瘤生物治疗学》", 30 April 2006, 广东科技出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641002A (zh) * 2016-08-02 2019-04-16 美国杰龙生物医药公司 血液癌症的组合治疗
US11278561B2 (en) 2016-08-02 2022-03-22 Geron Corporation Combination treatment for hematological cancers
CN109641002B (zh) * 2016-08-02 2022-10-18 美国杰龙生物医药公司 血液癌症的组合治疗
CN108732280A (zh) * 2017-04-18 2018-11-02 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法

Also Published As

Publication number Publication date
US20140134265A1 (en) 2014-05-15
US9717731B2 (en) 2017-08-01
US20140371241A1 (en) 2014-12-18
AU2018233032A1 (en) 2018-10-11
MX2015005633A (es) 2016-02-03
WO2014071231A1 (en) 2014-05-08
JP2019031506A (ja) 2019-02-28
US20180071293A1 (en) 2018-03-15
TN2015000170A1 (en) 2016-10-03
SG11201503459SA (en) 2015-06-29
EP2914263A4 (en) 2016-04-27
BR112015010059A2 (pt) 2017-07-11
HK1214508A1 (zh) 2016-07-29
DOP2015000098A (es) 2015-06-30
JP2015536950A (ja) 2015-12-24
PH12015500985A1 (en) 2015-08-03
AU2020220205A1 (en) 2020-09-10
AU2013337663A1 (en) 2015-06-11
TW201427664A (zh) 2014-07-16
NI201500062A (es) 2016-02-16
AU2018233032B2 (en) 2020-05-21
CA2890111A1 (en) 2014-05-08
KR20150080592A (ko) 2015-07-09
PE20151604A1 (es) 2015-11-04
CL2015001147A1 (es) 2015-06-26
JP2020183413A (ja) 2020-11-12
EA201590822A1 (ru) 2016-01-29
MX2021003018A (es) 2021-05-27
IL238548A0 (en) 2015-06-30
EP2914263A1 (en) 2015-09-09
CR20150242A (es) 2015-08-17
CN111329989A (zh) 2020-06-26
US20200147084A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2018233032B2 (en) TEC family kinase inhibitor adjuvant therapy
JP7295283B2 (ja) Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
US20250345335A1 (en) Methods of treating and preventing graft versus host disease
CN111373055B (zh) 用于癌症的诊断和治疗方法
JP6588461B2 (ja) 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
JP6508785B2 (ja) ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
KR20180126497A (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
JP2016534044A (ja) 癌の免疫療法のためのｃｂｐ／ｅｐ３００ブロモドメインインヒビターの使用
KR20160104612A (ko) 비산트렌의 치료 효과 개선용 조성물
JP6764017B2 (ja) がんの処置での使用のためのコビシスタット
WO2021096888A1 (en) Methods of detecting a fusion gene encoding a neoantigen
CN113271948B (zh) 治疗癌症的联合疗法
TW202448508A (zh) 治療癌症之方法及組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Illinois State

Applicant after: PHARMACYCLICS LLC

Address before: Illinois State

Applicant before: PHARMACYCLICS, Inc.

Address after: Illinois State

Applicant after: PHARMACYCLICS, Inc.

Address before: California, USA

Applicant before: PHARMACYCLICS, Inc.

COR Change of bibliographic data
CB02 Change of applicant information

Address after: California, USA

Applicant after: PHARMACYCLICS LLC

Address before: Illinois State

Applicant before: PHARMACYCLICS LLC

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20151021

RJ01 Rejection of invention patent application after publication